LONDON, January 9 /PRNewswire/ -- UK medical technology company BioCeramic Therapeutics Ltd is delighted to announce that Dr Stephan Rietiker has joined the company's Board of Directors. Dr Rietiker is widely recognized as a leading authority in BioCeramic Therapeutics' targeted sectors, particularly as former President and CEO of Centerpulse (formerly Sulzer Medical). His appointment follows the recent appointment of another renowned figure, Sir Richard Sykes, as Chairman of its Board of Directors and strengthens the company's management as it embarks on a new fundraising round to take its products through clinical trials.
"Given my professional background as a healthcare executive and in particular at Centerpulse, my primary focus is on getting involved in companies with leading edge technologies. As R&D activities in the biomaterials' arena are visibly gaining momentum, I'm delighted to be part of this fascinating venture. I fully believe in the technology and its future potential. Hence, I look forward to supporting the management team in efficiently reaching its strategic milestones and in creating significant value, both for patients and shareholders."
BCT is a pioneer in the exciting new field of regenerative medicine, bringing together some of the world's best materials scientists doctors, biologists and chemists in both private and public sectors. BCT is developing two families of implants designed to promote tissue regeneration. Initial applications are in orthopaedics and oral care, with plans to extend this to a wide range of other tissues important in human diseases.
Daniel Green, BCT's CEO, said: "I am delighted to welcome Stephan to the team. His input will be invaluable as we look to move our first BCT pipeline products through to clinic. Currently we are both exploring several licencing opportunities and embarking on a new fundraising round."
|SOURCE BioCeramic Therapeutics Ltd|
Copyright©2009 PR Newswire.
All rights reserved